Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Total Revenue by Product
Licensing and royalty revenue$191K$167K
Research fees$8.12M+5.7%$7.68M-12.9%$8.82M+32.8%$6.64M+63.2%$4.07M-14.7%
Accounts Receivable by Geography
CA-BC$17.72M$17.28M-2.1%$17.66M-17.7%$21.45M
Canada$12.49M$21.57M-16.0%$25.69M+30.5%$19.68M
Funding commitment received by Geography
CA-BC$35.5M$75M0.0%$75M0.0%$75M
Canada$94.4M
Accrued grants receivable by Geography
CA-BC$17.7M
Canada$12.5M
Government Assistance, Liability by Geography
CA-BC$24.79M$25.64M-1.6%$26.06M-1.4%$26.42M
Canada$81.15M$81.34M-1.7%$82.74M-1.8%$84.22M
Government assistance, award amount, undrawn grant funding by Geography
CA-BC$60.2M
Canada$111.8M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How does AbCellera Biologics Inc. break its business down?
AbCellera Biologics Inc. (ABCL) reports total revenue by product across 2 parts — Licensing and royalty revenue and Research fees. Each is extracted from the segment footnotes and tracked over time.
Where does AbCellera Biologics Inc.'s segment data come from?
Segment breakdowns are pulled from the segment footnotes in AbCellera Biologics Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.